GA-arm, remifentanil

PreclinicalSmall molecule

RRegion Skane

GA-arm, remifentanil is one of 5 small molecule programs targeting Regional Anesthesia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Regional AnesthesiaCompleted

Regional AnesthesiaPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Regional Anesthesia

#DrugCompanyPhaseTrials

Naropin

FFresenius Kabi USA, LLC

Approved

7 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

5 3

Xylocaine

MMEDRx USA, Inc.

Approved

2 4

Marcaine

IInnocoll

Phase 3

5 5

GA-arm, remifentanil

RRegion Skane

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Regional Anesthesia1 trial

General or Regional Anesthesia for Hip Surgery

Completed·RRegion Skane·N/A·NCT01733472·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GA-arm, remifentanil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GA-arm, remifentanil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GA-arm, remifentanil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Skane company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRegion Skane

GA-arm, remifentanil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Regional Anesthesia1 trial

References

Drug Info

Quick Facts

Related News